Six platforms.
Two portfolios.
The NexushriLabs portfolio covers pharmacovigilance, oncology research, clinical evidence, GxP operations, and women's health. Each platform is built for the compliance and documentation requirements that pharmaceutical organizations operate under. Platform names are withheld while provisional patent filings are in progress.
AI platform for pharmacovigilance and safety intelligence.
AI platform for oncology research intelligence.
AI platform for clinical evidence and regulatory intelligence.
AI platform for GxP biobank intelligence.
AI platform for pharmaceutical manufacturing intelligence.
AI platform for drug target identification and discovery.
Fertility status testing today is reactive, expensive, and rarely accessible before a woman reaches crisis point. This platform identifies novel blood-based reproductive biomarkers and translates them into a fertility status assessment that physicians and patients can use for proactive planning. ARPA-H solution summary submitted July 2026.
Endometriosis affects one in ten women and carries a diagnosis delay averaging seven to ten years. This platform applies multi-omics target discovery to identify candidates for non-surgical treatment, working toward therapies that address the disease rather than manage its symptoms.
Safety science and toxicology prediction remain high-cost, slow, and dependent on methods that were not designed for the volume of compounds modern drug discovery generates. This platform applies AI to toxicology classification and safety prediction across pharmaceutical, environmental, and therapeutic applications.
NexushriLabs has additional platforms in active development. Details will be shared following provisional patent clearance and completion of ongoing federal review processes.
One architecture.
Every platform.
The NexushriLabs stack was designed for regulated data from the start. Validated inputs, traceable reasoning, and auditable outputs are not features added after the fact. They are how the system is built. Each platform in the portfolio runs on the same underlying architecture, which means the compliance properties are consistent across the suite.
The work is underway.
NexushriLabs formed in February 2026. Since then the company has filed for federal grant eligibility, submitted to ARPA-H, established business banking, and built out the platform portfolio. The milestones below cover the first five months of operation.
Socioeconomic representations made by the company in the System for Award Management. Self-certified status, not issued by a certifying authority.
Applications will be submitted to SBA following completion of SAM.gov registration.
Announcements
Three Solution Summaries submitted to ARPA-H under the 2026 SBIR solicitation, covering the Fertility Intelligence Platform, Endometriosis Precision Therapy, and Toxicology and Safety Science.
Nexushri LLC has been assigned a Unique Entity Identifier in the System for Award Management. Registration is in progress.
The science is real.
The platforms are built.
NexushriLabs is founded and led by Jayashri Prasanan, a doctoral scientist, builder, and entrepreneur with deep knowledge of regulatory science, GxP frameworks, and the structural gaps in how software serves pharma, biotech, life sciences, and healthcare.
“NexushriLabs exists because the pain points were real and the solutions were not.”
Jayashri Prasanan, Founder & CEO
Why NexushriLabs
Talk to us.
Whether you are exploring a pilot, considering an investment, looking for a research partner, or have a question about the platform portfolio, reach out directly.